Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multiple-Dose, Randomized, Open-Label, Parallel Pharmacokinetic Comparison Study of TNX-102 SL (Cyclobenzaprine Hydrochloride [HCl] Sublingual Tablets) 2 x 2.8 mg Versus AMRIX (Cyclobenzaprine HCl ER Capsules) 30 mg in Healthy Subjects Under Fasting Conditions

Next Previous
Trial Profile

A Multiple-Dose, Randomized, Open-Label, Parallel Pharmacokinetic Comparison Study of TNX-102 SL (Cyclobenzaprine Hydrochloride [HCl] Sublingual Tablets) 2 x 2.8 mg Versus AMRIX (Cyclobenzaprine HCl ER Capsules) 30 mg in Healthy Subjects Under Fasting Conditions

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cyclobenzaprine (Primary) ; Cyclobenzaprine
  • Indications Agitation; Post-traumatic stress disorders
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Tonix Pharmaceuticals Inc

Most Recent Events

  • 30 May 2019 According to a Tonix Pharmaceuticals Holding Corp media release, data were presented at the American Society of Clinical Psychopharmacology (ASCP) 2019.
  • 24 May 2018 According to a Tonix Pharmaceuticals Holding Corp media release, preliminary results from this study supports the 505(b)(2) NDA submission for TNX-102 SL.
  • 24 May 2018 Preliminary results presented in a Tonix Pharmaceuticals Holding Corp Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top